New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Epax named NBT award finalist

Epax named NBT award finalist
Company was nominated for its DHA fatty acid product, EPAX 1050 TG.

The Nutraceutical Business & Technology (NBT) selected Epax as a finalist in the Outstanding Application in Health Management category. All finalists will be recognized at the NBT awards ceremony in connection with Vitafoods Europe on May 14 to 16, 2013 in Geneva, Switzerland.

Epax was nominated for its DHA fatty acid product, EPAX 1050 TG, in an application called “Food for Thought”. The development process sought to demonstrate the anti-dementia effects of EPAX 1050 TG, a high DHA- concentrate omega-3 fatty acid. Process chemists, quality assurance experts, experienced biologists and scientific trained clinicians at Epax worked together with a Swedish and a Canadian group of scientists to test whether EPAX 1050 TG could reduce the propensity for development of brain amyloid leading to deterioration of brain cells. The project was unique in demonstrating positive effects of a food supplement with a semi-pharmaceutical development program.

“Epax will continue to be involved in applications focused on brain health,” said Gunilla Traberg, head of marketing for Epax. “Providing the most clinically researched marine omega-3 ingredients, our efforts will continue with research on how DHA supplementation can support cognitive health. The opportunities for applications in this area are abundant”.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.